Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
19 July 2018 Photo Supplied
AEVGI advances Next-Generation Sequencing in Africa
Prof George Armah, Noguchi Memorial Institute for Medical Research, Ghana; Prof Carl Kirkwood, Bill and Melinda Gates Foundation, USA; Cornelius Hagenmeier, Director: Internationalisation, UFS; Prof Gert van Zyl, Dean: Health Sciences; Dr Martin Nyaga, Senior Lecturer in the NGS Unit; Prof Joyce Tsoka-Gwegweni, Vice-Dean: Health Sciences; Dr Glen Taylor, Senior Director: Research and Development; Prof Jeffrey Mphahlele, Vice-President, South African Medical Research Council.

The inaugural edition of the University of the Free State (UFS) Next-Generation Sequencing (NGS) Data and Bioinformatics Workshop, hosted by the UFS-NGS Unit in the UFS Faculty of Health Sciences, marked a new beginning for the advancement of NGS in Africa under the auspices of the African Enteric Viruses Genome Initiative (AEVGI), which was recently funded by the Bill and Melinda Gates Foundation.

The AEVGI will generate rotavirus genomes at the UFS-NGS Unit to investigate the long-term effects of the introduction of the monovalent RV1 vaccine in three African countries – Ghana, Malawi, and South Africa.

The workshop attracted over 90 participants from 15 national and international institutions, with organisations from seven different countries as well as company representatives attending the event. The workshop kicked off with a courtesy call to the Rector and Vice-Chancellor, Prof Francis Petersen, followed by a stakeholder meeting with the executive management of the UFS.

The funding was secured through an award to the principal investigator, Dr Martin Nyaga, and sub-awards to co-investigators, Dr Khuzwayo Jere, Dr Francis Dennis, and Dr Valentine Ndze. According to attendee evaluations of the workshop, the remarkable performance of the workshop instructors was outstanding. Through practical sessions, participants were equipped with knowledge on how to apply several tools of genetic data analysis, using the rotavirus genome as a model to construct and interpret different genomic datasets.

A total of 65 students attended the hands-on workshop, the majority of which were from South African higher-education institutions. The organisers are grateful to the sponsors, particularly to the Bill and Melinda Gates Foundation and the University of the Free State, for making the workshop a success. Whitehead Scientific and the South African Medical Research Council also played a major role in the success of the workshop. The local organising committee consisted of Dr Martin Nyaga (host, convener and chair), Dr Saheed Sabiu (secretary), and Mr Stephanus Riekert (principal ICT support).

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept